Aureus Asset Management LLC Invests $1.22 Million in United Therapeutics Corporation $UTHR

Aureus Asset Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,500 shares of the biotechnology company’s stock, valued at approximately $1,218,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $48,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

UTHR opened at $551.47 on Thursday. The firm’s fifty day moving average is $565.95 and its two-hundred day moving average is $522.96. The firm has a market cap of $23.41 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $6.63 earnings per share. Equities analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $549.17, for a total value of $5,491,700.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,366,132.92. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $24,712,246.04. This trade represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 636,168 shares of company stock worth $359,249,237. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on UTHR. HC Wainwright boosted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Royal Bank Of Canada dropped their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.